Lara Sullivan, MD, President and Founder at SpringWorks Therapeutics discusses the mechanism of action of Senicapoc (a Gardos channel blocker), an emerging treatment for Hereditary Xerocytosis, a genetic disorder in which red blood cells become dehydrated due to loss of potassium and cell water.

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.